An Open, Parallel, Single-dose Phase I Clinical Study to Evaluate the Pharmacokinetics and Safety of TQ05105 Tablets in Patients With Different Levels of Renal Function
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Rovadicitinib (Primary)
- Indications Myelofibrosis
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 01 Oct 2024 New trial record